Orphan drug pricing may warrant a competition law investigation

Jonathan C. P. Roos · Hanna I. Hyry · Timothy Martin Cox

53 citations0/0 files storedBMJ

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Merger and Competition Analysis Diverse Legal and Medical Studies

Abstract

EU legislation offers an exclusive marketing period as an incentive for companies to develop drugs for rare diseases. But pricing for orphan drugs hinders access and may warrant a competition law investigation, say Jonathan C P Roos, Hanna I Hyry, and Timothy M Cox

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 53 citations exist upstream.

Cited by

2011Drugs for Rare Diseases: Influence of Orphan Designation Status on Price 2012The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs 2012Unintended effects of orphan product designation for rare neurological diseases

Imported from OpenAlex (CC0) — nothing here is generated.